Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. (“Enfusion” or “the Company”) (NYSE: ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ENFN.

Investigation Details

On August 6, 2024, Enfusion reported its financial results for the second quarter of 2024. The Company missed consensus estimates for both earnings and revenue. Following this news, Enfusion stock dropped 7.86% on that same day.

What's Next?

If you are aware of any facts relating to this investigation or purchased Enfusion securities, you can assist this investigation by visiting the firm’s site: bgandg.com/ENFN. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240822206806/en/

The Enfusion Registered (A) Stock at the time of publication of the news with a raise of +1,49 % to 8,20USD on NYSE stock exchange (22. August 2024, 02:04 Uhr).